Download Files:
Patisiran (sodium)
$1,000 – $4,800
Products Details
Product Description
– Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis[1][2][3].
Web ID
– HY-132609
Storage Temperature
– -20°C (Powder, stored under nitrogen)
Shipping
– Blue Ice
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– N/A
References
– [1]Adams D, et, al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21.|[2]Hoy SM. Patisiran: First Global Approval. Drugs. 2018 Oct;78(15):1625-1631.|[3]Kristen AV, et, al. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag. 2019 Feb;9(1):5-23.
CAS Number
– 1386913-72-9
Molecular Weight
– 13427.10 (AS: 6661.3; SS: 6765.8)
Compound Purity
– 96.72
SMILES
– [Patisiran (sodium)]
Clinical Information
– Launched
Research Area
– Neurological Disease
Solubility
– H2O : 33.33 mg/mL (ultrasonic)
Target
– Small Interfering RNA (siRNA);Transthyretin (TTR)
Pathway
– Epigenetics;Neuronal Signaling
Product type
– Oligonucleotides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
